Whole exome sequencing (WES) uses next-generation sequencing (NGS) to target the protein-coding regions of the genome, known as the exome. Although the exome represents only 1-2% of the human genome, it contains about 85% of known mutations linked to Mendelian disorders, making WES a cost-effective alternative to whole genome sequencing (WGS). By focusing on these critical regions, WES delivers deep coverage to identify germline and somatic mutations, supporting diverse research areas including genetic disorders, complex diseases, cancer, and population genetics.
Novogene offers extensive experience in whole exome sequencing with a range of commercial WES panels. Our service provides high-quality data and comprehensive bioinformatics analysis, complete with variant annotation and publication-ready figures.





